Stay Ahead with the Latest in Finance

KeyBanc raises Parsons Corporation’s stock price target to $93 from $87, indicating a positive outlook for the company’s future performance.

Replimune’s acceptance of its melanoma treatment BLA signals potential market opportunities and advancements in immuno-oncology.

Freightos reports a 27% growth in Q3 transactions, reflecting strong performance driven by market demand and strategic innovations.

Collective Mining announces promising mineralization findings in Colombia, emphasizing the growth potential in the mining sector.

Glaukos has received FDA approval for a new incision-free treatment for keratoconus, marking a significant milestone in ophthalmic innovation.

Fortrea has announced a $75.7 million debt tender offer to enhance its financial position and optimize its capital structure.

Enanta’s recent clinical trial results for RSV treatments show promise, signaling potential breakthroughs in addressing respiratory infections.

Vivid Seats plans to eliminate dual-class shares to simplify its corporate structure and align with investor interests.

GoldMining announces new gold targets at São Jorge, signaling potential market growth and investment opportunities.